These innovative agents represent a significant leap in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://haleemaleqm598339.blogsumer.com/38118632/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide